Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHENASDAQ:INKTNASDAQ:MRNSNASDAQ:TSBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$3.46-0.3%$3.49$1.00▼$5.87$30.68M0.71137,798 shs5,551 shsINKTMiNK Therapeutics$7.58-3.6%$8.27$4.56▼$13.79$31.18M0.1514,557 shs1,649 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.72 million shs260 shsTSBXTurnstone Biologics$0.37+8.0%$0.37$0.29▼$3.39$8.45M1.3217,651 shs27,541 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-0.29%0.00%+0.87%+4.68%+58.09%INKTMiNK Therapeutics+5.01%+4.38%-12.96%+19.09%-17.27%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%+1.09%-60.78%TSBXTurnstone Biologics-0.88%+8.89%-18.00%-30.52%-87.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHEAlterity Therapeutics1.8287 of 5 stars3.33.00.00.01.81.70.0INKTMiNK Therapeutics2.7499 of 5 stars3.53.00.00.03.31.70.6MRNSMarinus Pharmaceuticals1.937 of 5 stars3.20.00.04.20.01.70.6TSBXTurnstone Biologics2.4239 of 5 stars1.85.00.00.03.32.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00246.82% UpsideINKTMiNK Therapeutics 3.00Buy$37.50395.05% UpsideMRNSMarinus Pharmaceuticals 2.40Hold$4.79771.56% UpsideTSBXTurnstone Biologics 1.50Reduce$0.4523.29% UpsideCurrent Analyst Ratings BreakdownLatest TSBX, ATHE, MRNS, and INKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.002/25/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $35.002/5/2025TSBXTurnstone BiologicsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$3.75 ➝ $0.402/3/2025ATHEAlterity TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSpeculative Buy ➝ Hold1/30/2025ATHEAlterity TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $12.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($5.23) per shareN/AMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77TSBXTurnstone Biologics$19.31M0.44N/AN/A$4.27 per share0.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/AN/AINKTMiNK Therapeutics-$22.46M-$2.92N/AN/AN/AN/AN/A-189.14%5/13/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%5/6/2025 (Estimated)TSBXTurnstone Biologics-$55.20M-$3.07N/AN/AN/AN/A-105.99%-87.27%5/12/2025 (Estimated)Latest TSBX, ATHE, MRNS, and INKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025INKTMiNK Therapeutics-$0.61N/AN/AN/AN/AN/A5/12/2025Q1 2025TSBXTurnstone Biologics-$0.26N/AN/AN/AN/AN/A3/28/2025Q4 2024TSBXTurnstone Biologics-$0.69-$0.56+$0.13-$0.56N/AN/A3/18/2025Q4 2024INKTMiNK Therapeutics-$0.50-$0.62-$0.12-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ATSBXTurnstone BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A3.543.54INKTMiNK TherapeuticsN/A0.890.89MRNSMarinus PharmaceuticalsN/A1.661.47TSBXTurnstone BiologicsN/A3.753.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%INKTMiNK Therapeutics2.87%MRNSMarinus Pharmaceuticals98.80%TSBXTurnstone Biologics52.51%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%INKTMiNK Therapeutics20.60%MRNSMarinus Pharmaceuticals5.46%TSBXTurnstone Biologics32.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.35 millionNot OptionableINKTMiNK Therapeutics303.97 million3.15 millionNo DataMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableTSBXTurnstone Biologics8223.14 million15.70 millionNot OptionableTSBX, ATHE, MRNS, and INKT HeadlinesRecent News About These CompaniesTurnstone Biologics reports Q4 EPS (56c) vs (73c) last yearMarch 31, 2025 | markets.businessinsider.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | investing.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | globenewswire.comTurnstone Biologics stock plunges to 52-week low of $0.4February 11, 2025 | msn.comTurnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?February 7, 2025 | zacks.comTurnstone Biologics to explore strategic alternativesFebruary 6, 2025 | thepharmaletter.comTurnstone ends last remaining clinical program due to costs, plots more layoffsFebruary 5, 2025 | fiercebiotech.comTurnstone Biologics halts TIDAL-01 development, seeks alternativesFebruary 5, 2025 | msn.comTurnstone Biologics downgraded to Neutral from Overweight at Piper SandlerFebruary 5, 2025 | markets.businessinsider.comTurnstone Biologics Corp (TSBX) Stock: A Deeper Look at Its True PotentialFebruary 5, 2025 | bovnews.comTurnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives ReviewFebruary 4, 2025 | quiverquant.comTurnstone Biologics Announces Plans to Explore Strategic AlternativesFebruary 4, 2025 | finance.yahoo.comBofA downgrades Turnstone to Underperform on unfavorable marketNovember 16, 2024 | markets.businessinsider.comTurnstone Biologics downgraded to Underperform from Neutral at BofANovember 16, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Hold Rating on Turnstone Biologics Corp. (TSBX)November 15, 2024 | markets.businessinsider.comTurnstone Biologics Faces Financial and Operational ChallengesNovember 14, 2024 | markets.businessinsider.comTurnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business HighlightsNovember 12, 2024 | markets.businessinsider.comWhat’s Behind the 18.75% Gain in Turnstone Biologics Corp (TSBX) Stock? Find Out Now!November 7, 2024 | bovnews.comTurnstone Biologics presents two posters on methods for TIL selection at SITCNovember 6, 2024 | markets.businessinsider.comTurnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 5, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonRocket Lab Stock: Weathering the Storm, Time for a Comeback?By Ryan Hasson | April 11, 2025View Rocket Lab Stock: Weathering the Storm, Time for a Comeback?American Express: Affluent Customers Don’t Leave Home Without It By Jea Yu | April 26, 2025View American Express: Affluent Customers Don’t Leave Home Without It TSBX, ATHE, MRNS, and INKT Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$3.46 -0.01 (-0.29%) As of 03:02 PM EasternAlterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.MiNK Therapeutics NASDAQ:INKT$7.58 -0.29 (-3.63%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Turnstone Biologics NASDAQ:TSBX$0.36 +0.03 (+8.02%) As of 03:23 PM EasternTurnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
